Gilead's Remdesivir Shows Consistent Efficacy In Patients With Comorbidities With Higher Risk for Severe COVID-19

Loading...
Loading...

Gilead Sciences Inc GILD announced full results from a Phase 3 study of a three-day course of Veklury (remdesivir) non-hospitalized COVID-19 patients at high risk for disease progression. 

  • Participants receiving Veklury treatment had an 87% reduction in risk for the composite primary endpoint of COVID-19-related hospitalization or all-cause death by Day 28.
  • There was an 81% reduction in the risk for the composite secondary endpoint of COVID-19-related medical visits due to COVID-19 or all-cause death by Day 28 compared to placebo. 
  • Related: European Commission Expands Use Of Remdesivir In COVID-19 Patients Not On Supplemental Oxygen
  • There was no difference observed in nasopharyngeal SARS-CoV-2 viral load up to Day 7 between groups, indicating that upper respiratory viral loads do not reliably predict treatment outcomes in COVID-19. 
  • No deaths were observed in either arm in the study by Day 28.
  • The study includes new subgroup analyses which showed consistent efficacy of Veklury for patients irrespective of their key risk factors for severe COVID-19. 
  • Participants with comorbidities had a reduced risk of COVID-19-related hospitalization by Day 28 with Veklury treatment.
  • The safety profile was similar between Veklury and placebo across the variety of outpatient settings in this trial. 
  • The most common treatment-emergent adverse events in patients taking Veklury were nausea and headache. 
  • Price Action: GILD shares closed 0.23% at $72.60 during after-hours trading on Wednesday.
Loading...
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 CoronavirusPhase 3 Trial
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...